Last reviewed · How we verify
NCT06662162: i-SIGHT2
Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration
NA trial testing i-Lumen AMD in Age-Related Macular Degeneration in 100 participants. Currently enrolling.
31 March 2027
Quick facts
| Lead sponsor | i-Lumen Scientific AUS PTY LTD |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 100 |
| Start date | 7 May 2025 |
| Primary completion | 31 March 2027 |
| Estimated completion | 31 December 2029 |
| Sites | 10 locations across New Zealand, United Kingdom, United States, Australia |
Drugs / interventions tested
- i-Lumen AMD
Conditions studied
- Age-Related Macular Degeneration — all drugs for Age-Related Macular Degeneration →
- Age-related Macular Degeneration (ARMD) — all drugs for Age-related Macular Degeneration (ARMD) →
- Intermediate AMD — all drugs for Intermediate AMD →
- Geographic Atrophy Secondary to Age-related Macular Degeneration — all drugs for Geographic Atrophy Secondary to Age-related Macular Degeneration →
Sponsor
i-Lumen Scientific AUS PTY LTD
Who can join
60 and older, any sex, with Age-Related Macular Degeneration or Age-related Macular Degeneration (ARMD). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to characterize the safety and effectiveness of the i-Lumen AMD transpalpebral microcurrent device and therapy in patients with intermediate to advanced nonexudative AMD. Participants will: * Undergo an initial loading regimen, followed by 7 maintenance over the course of 11 months. * Participants will return monthly through Month 14 (3 months post-last treatment) for evaluation and monitoring.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06662162
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of i-Lumen AMD
Trials testing the same drug.
- NCT04511936 — Microcurrent Stimulation for Dry Age-related Macular Degeneration · NA · withdrawn
Other recruiting trials for Age-Related Macular Degeneration
Currently open trials in the same condition.
- NCT07440225 — A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002) · Phase 2, PHASE3 · recruiting
- NCT06619405 — AMD and Validation Rod-Meditated Dark Adaptation With Everyday Task Performance · NA · recruiting
- NCT06970665 — A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Ma · Phase 4 · recruiting
- NCT06319872 — The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration · Phase 1 · recruiting
- NCT06593405 — The Role of Occupational Therapy for Improving Medication Management for Persons With AMD, DR and Glaucoma · EARLY_PHASE1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06662162 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by i-Lumen Scientific AUS PTY LTD
- Last refreshed: 14 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06662162.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing